Is CRISPR Therapeutics (CRSP) One Of The Under-The-Radar Stocks With Massive Upside For 2026?

With an analyst consensus upside of 52.3%, CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the under-the-radar stocks with massive upside for 2026.

As CASGEVY reinforced confidence in the company’s long-term growth outlook, CRISPR Therapeutics AG (NASDAQ:CRSP) received fresh support from Wall Street.

On May 13, 2026, Bernstein raised its price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $56 from $50 while keeping a “Market Perform” rating. The firm pointed to a strong start for biotech in 2026, with the sector up 11% year-to-date and outperforming both pharma and the S&P 500. Bernstein maintained a positive view on the space, citing expectations for healthy M&A and IPO activity and characterizing recent FDA leadership changes as a tailwind, particularly for less mature companies.

That update followed Q1 2026 results reported on May 4, 2026.

CASGEVY, the company’s approved gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia (TDT), generated $43 million in revenue during the quarter, with more than 500 patients having initiated treatment worldwide. Net loss narrowed to $122.9 million, or $1.28 per share, from $136.0 million a year earlier. R&D expenses came in at $68.6 million and G&A at $17.2 million, both lower than the prior-year period.

Cash, cash equivalents, and marketable securities strengthened to $2.44 billion as of March 31, 2026, up from $1.98 billion at year-end 2025, driven largely by $585.4 million in net proceeds from convertible senior notes issued in March. CEO Samarth Kulkarni said 2026 “will be a defining year” for CRISPR Therapeutics AG (NASDAQ:CRSP), citing pipeline milestones ahead.

Meanwhile, on May 5, 2026, BofA trimmed its price target to $83 from $86 but kept a “Buy” rating, saying the Q1 updates left its core thesis largely unchanged.

Overall, 14 out of 26 covering analysts hold bullish views on CRISPR Therapeutics AG (NASDAQ:CRSP).

CRISPR Therapeutics AG (NASDAQ:CRSP) develops gene-editing therapies for serious diseases using its CRISPR/Cas9 platform technology.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.